Transplanting the genetic susceptibility to Crohn s disease

Gut

Volumn 52, Issue 10, 2003, Pages 1394-1396

  Holtmann, M H ^a   Neurath, M F ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CROHN DISEASE; DISEASE PREDISPOSITION; GENE MUTATION; GENETIC ANALYSIS; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEREDITY; HUMAN; IMMUNOPATHOGENESIS; MOLECULAR GENETICS; NONHUMAN; NOTE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR;

5' UNTRANSLATED REGIONS; CARRIER PROTEINS; CROHN DISEASE; GENETIC PREDISPOSITION TO DISEASE; HODGKIN DISEASE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NOD2 SIGNALING ADAPTOR PROTEIN; POLYMORPHISM, GENETIC; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 0141757444     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.52.10.1394     Document Type: Note

References (17)

1. Duchmann R, Zeitz M. Crohn's disease. In: Ogra P, Strober W, eds. Handbook of mucosal immunology. San Diego: Academic Press, 1999:1005.
2. Shanahan F. Crohn's disease. Lancet 2002;359:62-9.
3. Atreya R, Mudter J, Finotto S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med 2000;6:583-8.
4. Powrie F, Leach MW, Mauze S, et al. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1994;2:553-62.
5. Holtmann MH, Douni E, Schutz M, et al. Tumor necrosis factor-receptor 2 is upregulated on lamina propria mononuclear cells in Crohn's disease and promotes experimental colitis in vivo. Eur J Immunol 2002;32:3142-51.
6. Neurath MF, Fuss I, Kelsall BL, et al. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995;182:1281-90.
7. Lopez-Cubero SA, Sullivan KM, McDonald GB. Course of Crohn's disease after allogenic bone marrow transplantation. Gastroenterology 1998;114:433-40.
8. James SP. Remission of Crohn's disease after human immunodeficiency virus infection. Gastroenterology 1988;95:1667-9.
9. ten Hove T, van Montfrans C, Peppelenbosch MP, et al. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002;50:206-11.
10. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003;111:1133-45.
11. Sonwalkar SA, James RM, Ahmad T, et al. Fulminant Crohn's colitis after allogeneic stem cell transplantation. Gut 2003;52:1518-21.
12. Curran ME, Lau KF, Hampe J, et al. Genetic analysis of inflammatory bowel disease in a large European cohort supports linkage to chromosomes 12 and 16. Gastroenterology 1998;115:1066-71.
13. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-6.
14. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603.
15. Hisamatsu T, Suzuki M, Reinecker HC, et al. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology 2003;124:993-1000.
16. Abreu MT, Taylor KD, Lin YC, et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology 2002;123:679-88.
17. Schölmerich J. New developments in aetiological mechanisms of inflammatory bowel disease. Eur J Gastroenterol Hepatol 2003;15:585-6.